NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed an agreement to commercialize its SelectMDx prostate cancer test in France, Belgium, and Luxembourg through Cerba HealthCare Belgium.
Under the terms of the two-year deal, Cerba will offer the test through its laboratory network, initially analyzing patient samples at MDxHealth's service-testing lab in the Netherlands. Later, Cerba will begin testing samples at its own medical biology test lab in Belgium.
Additional terms were not disclosed.
SelectMDx is a urine-based assay designed to identify men at high risk for aggressive prostate cancer who may benefit from early detection and an initial prostate biopsy or MRI, as well as those at very low risk for this disease.
Earlier this year, MDxHealth signed an agreement giving the Andros Men's Health Clinic the rights to offer the test in the Netherlands